Cargando…
Changes in Medicare Part B Spending for Biologic Drugs After Biosimilar Entry Into the Market
This cross-sectional study describes changes in annual Medicare Part B spending for biologic drugs after biosimilar entry, focusing on the first 4 products to experience biosimilar competition: filgrastim, infliximab, epoetin alpha, and pegfilgrastim.
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8796923/ https://www.ncbi.nlm.nih.gov/pubmed/35977178 http://dx.doi.org/10.1001/jamahealthforum.2021.2634 |
_version_ | 1784641425001938944 |
---|---|
author | Dean, Emma Boswell Bond, Amelia M. |
author_facet | Dean, Emma Boswell Bond, Amelia M. |
author_sort | Dean, Emma Boswell |
collection | PubMed |
description | This cross-sectional study describes changes in annual Medicare Part B spending for biologic drugs after biosimilar entry, focusing on the first 4 products to experience biosimilar competition: filgrastim, infliximab, epoetin alpha, and pegfilgrastim. |
format | Online Article Text |
id | pubmed-8796923 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | American Medical Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-87969232022-02-07 Changes in Medicare Part B Spending for Biologic Drugs After Biosimilar Entry Into the Market Dean, Emma Boswell Bond, Amelia M. JAMA Health Forum Research Letter This cross-sectional study describes changes in annual Medicare Part B spending for biologic drugs after biosimilar entry, focusing on the first 4 products to experience biosimilar competition: filgrastim, infliximab, epoetin alpha, and pegfilgrastim. American Medical Association 2021-09-17 /pmc/articles/PMC8796923/ /pubmed/35977178 http://dx.doi.org/10.1001/jamahealthforum.2021.2634 Text en Copyright 2021 Dean EB et al. JAMA Health Forum. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the CC-BY License. |
spellingShingle | Research Letter Dean, Emma Boswell Bond, Amelia M. Changes in Medicare Part B Spending for Biologic Drugs After Biosimilar Entry Into the Market |
title | Changes in Medicare Part B Spending for Biologic Drugs After Biosimilar Entry Into the Market |
title_full | Changes in Medicare Part B Spending for Biologic Drugs After Biosimilar Entry Into the Market |
title_fullStr | Changes in Medicare Part B Spending for Biologic Drugs After Biosimilar Entry Into the Market |
title_full_unstemmed | Changes in Medicare Part B Spending for Biologic Drugs After Biosimilar Entry Into the Market |
title_short | Changes in Medicare Part B Spending for Biologic Drugs After Biosimilar Entry Into the Market |
title_sort | changes in medicare part b spending for biologic drugs after biosimilar entry into the market |
topic | Research Letter |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8796923/ https://www.ncbi.nlm.nih.gov/pubmed/35977178 http://dx.doi.org/10.1001/jamahealthforum.2021.2634 |
work_keys_str_mv | AT deanemmaboswell changesinmedicarepartbspendingforbiologicdrugsafterbiosimilarentryintothemarket AT bondameliam changesinmedicarepartbspendingforbiologicdrugsafterbiosimilarentryintothemarket |